# Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

> **NCT00513747** · PHASE3 · TERMINATED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 84 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00513747
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Insufficient accrual
- **Last updated:** 2020-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513747, "Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00513747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*